Skip to main
DYN

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 53%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

The positive outlook for Dyne Therapeutics Inc. is supported by recent data from its DELIVER trial, which has alleviated previous safety concerns and demonstrated significant functional superiority over existing standard care. The company's increasing confidence in the DYNE-251 and its pipeline, enhanced by favorable changes in price target and probability of success assumptions, reflects the potential for accelerated FDA approval and further market validation. Additionally, the therapeutic targets identified within the pipeline present commercially attractive indications, positioning Dyne favorably amid a competitive landscape and enhancing its appeal for potential acquisition opportunities.

Bears say

Dyne Therapeutics faces a challenging outlook primarily due to significant concerns surrounding its clinical pipeline, particularly the DYNE-101 and DYNE-251 candidates, which have not demonstrated a clear clinical signal and may be hindered by safety issues and a slow advancement in regulatory pathways for the DM1 program. Furthermore, the company is experiencing a notable trading discount relative to its competitor Avidity, attributed to investor apprehension about timelines, clinical trial outcomes, and the potential for accelerated approval. Additionally, the presence of competitive threats and the risk of emerging treatments may further undermine the market position of Dyne Therapeutics's cell-based therapies, creating a precarious environment for future growth.

Dyne Therapeutics (DYN) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 53% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 15 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.